Showing 5941-5950 of 9416 results for "".
- Depression, Psoriasis And Risk Of Psoriatic Arthritis: What's the Connection?https://practicaldermatology.com/news/depression-psoriasis-and-risk-of-psoriatic-arthritis-whats-the-connection/2458269/Psoriasis patients who develop depression are at a 37 percent greater risk of developing psoriatic arthritis, compared with psoriasis patients who did not develop depression, according to a new
- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved t
- DermMentors™ 2017 Resident of Distinction Award Honors Five Dermatology Residentshttps://practicaldermatology.com/news/dermmentors-2017-resident-of-distinction-award-honors-five-dermatology-residents/2458273/As part of the dermMentors™ Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 16th Annual Caribbean Dermatology Symposium in Aruba, Netherlands Antilles, from January 17 - 21, 2017
- Cloudy With a Chance of Wrinkles: Most Americans Fail to Protect Skin From Pollutionhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-most-americans-fail-to-protect-skin-from-pollution/2458275/Most Americans don’t protect their skin from pollutants even though they are aware of the harm that pollution and other environmental stressors can cause to skin, according to a new survey by H2O+ Beauty. Just 33 percent of people purchase
- CareCredit to Acquire CitiHealth Card Portfoliohttps://practicaldermatology.com/news/carecredit/2458277/CareCredit has signed an agreement with Citibank, N.A. to acquire the Citi Health Card portfolio, further expanding its healthcare acceptance network in the United States. The portfolio acquisition includes more than 14,500 providers,
- Vision Medical's SmartGraft Now Offers Articulating Arm With Mayo Trayhttps://practicaldermatology.com/news/vision-medicals-smartgraft-now-offers-articulating-arm-with-mayo-tray/2458276/SmartGraft® Hair Restoration is rolling out its first articulating arm and mayo tray, Vision Medical Inc., reports. Available in February, the SmartGraft AMT (articulating mayo tray) provides ergonomic design for physicians Available to ne
- Save The Dates: ASLMS to Host 37th Annual Conference In Early April 2017https://practicaldermatology.com/news/save-the-dates-aslms-to-host-37th-annual-conference-in-early-april-2017/2458279/American Society for Laser Medicine and Surgery (ASLMS) 2017 will take place April 5 – 9, 2017 in San Diego, Calif. New for 2017 is a special CME Session, Moving from the Lab to the Clinic, which will focus on the translation of technolog
- Researchers Discover New Antibiotic That May Fight MRSAhttps://practicaldermatology.com/news/researchers-discover-new-antibiotic-that-may-fight-mrsa/2458282/Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) have uncovered a new antibiotic that they say is potent against antibiotic-resistant ‘superbugs’ like methicillin resistant Staphylococcus aureus (MRSA). The researchers isolated
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo
- Hologic to Acquire Cynosurehttps://practicaldermatology.com/news/hologic-to-acquire-cynosure/2458288/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billi